Compare Stocks → top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:APLTNASDAQ:CERCNASDAQ:HOOKNASDAQ:MBIO Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPLTApplied Therapeutics$4.31-3.4%$5.88$1.09▼$9.39$509.52M1.81961,003 shs770,112 shsCERCCerecor$13.00+6.5%$2.60$1.98▼$4.50$1.25B1.441.27 million shs73,477 shsHOOKHookipa Pharma$0.85+10.4%$0.74$0.41▼$2.05$75.70M1.02574,477 shs10.42 million shsMBIOMustang Bio$0.35-2.8%$0.96$0.33▼$8.17$3.74M1.58258,707 shs123,283 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPLTApplied Therapeutics-3.36%-10.77%-36.15%+47.60%+220.71%CERCCerecor0.00%-18.44%+166.39%+217.07%+320.71%HOOKHookipa Pharma+11.11%+11.48%+20.98%+19.72%-10.62%MBIOMustang Bio-2.67%-8.83%-63.53%-75.35%-90.91%top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (Ad)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution…MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPLTApplied Therapeutics4.5001 of 5 stars4.53.00.04.70.03.30.6CERCCerecorN/AN/AN/AN/AN/AN/AN/AN/AHOOKHookipa Pharma3.6887 of 5 stars3.55.00.00.04.01.71.3MBIOMustang Bio2.0287 of 5 stars3.55.00.00.02.40.00.0Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPLTApplied Therapeutics3.00Buy$11.00155.22% UpsideCERCCerecorN/AN/AN/AN/AHOOKHookipa Pharma3.00Buy$5.17507.84% UpsideMBIOMustang Bio3.00Buy$17.254,827.16% UpsideCurrent Analyst RatingsLatest APLT, HOOK, CERC, and MBIO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/11/2024APLTApplied TherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$12.003/26/2024APLTApplied TherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$12.003/25/2024HOOKHookipa PharmaRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$5.003/25/2024HOOKHookipa PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.503/15/2024APLTApplied TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$12.00 ➝ $13.003/6/2024APLTApplied TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$4.00 ➝ $12.002/22/2024APLTApplied TherapeuticsLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform2/22/2024APLTApplied TherapeuticsSVB LeerinkSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$12.002/16/2024APLTApplied TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$5.00 ➝ $7.001/30/2024HOOKHookipa PharmaRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$6.00 ➝ $5.00(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPLTApplied Therapeutics$9.99M49.29N/AN/A($0.20) per share-21.55CERCCerecor$6.70M186.29N/AN/A$0.22 per share59.09HOOKHookipa Pharma$20.13M4.18N/AN/A$0.91 per share0.93MBIOMustang BioN/AN/AN/AN/A$0.01 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPLTApplied Therapeutics-$119.76M-$1.35N/AN/AN/AN/AN/A-275.83%5/9/2024 (Estimated)CERCCerecor-$63.50M-$0.57N/AN/AN/A-1,194.82%-261.82%-133.96%N/AHOOKHookipa Pharma-$81.58M-$0.88N/AN/AN/A-405.28%-72.30%-40.51%5/9/2024 (Estimated)MBIOMustang Bio-$51.60M-$6.00N/A∞N/AN/A-433.08%-146.39%5/10/2024 (Estimated)Latest APLT, HOOK, CERC, and MBIO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/22/2024Q4 2023HOOKHookipa Pharma-$0.20-$0.11+$0.09N/A$3.60 million$7.41 million3/11/2024Q4 2023MBIOMustang Bio-$1.68-$0.71+$0.97-$0.71N/AN/A3/6/2024Q4 2023APLTApplied Therapeutics-$0.15-$0.33-$0.18-$0.33N/A($0.67) millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPLTApplied TherapeuticsN/AN/AN/AN/AN/ACERCCerecorN/AN/AN/AN/AN/AHOOKHookipa PharmaN/AN/AN/AN/AN/AMBIOMustang BioN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPLTApplied TherapeuticsN/A0.760.76CERCCerecor0.792.192.18HOOKHookipa PharmaN/A3.503.50MBIOMustang BioN/A0.740.74OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPLTApplied Therapeutics98.31%CERCCerecor62.84%HOOKHookipa Pharma63.88%MBIOMustang Bio9.95%Insider OwnershipCompanyInsider OwnershipAPLTApplied Therapeutics19.10%CERCCerecor45.70%HOOKHookipa Pharma5.82%MBIOMustang Bio2.10%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAPLTApplied Therapeutics25114.24 million85.66 millionOptionableCERCCerecor3196.01 millionN/ANot OptionableHOOKHookipa Pharma5698.95 million93.19 millionOptionableMBIOMustang Bio8010.39 million10.17 millionNot OptionableAPLT, HOOK, CERC, and MBIO HeadlinesSourceHeadlineWorcester biotech down to 11 employees after asset sale stallsbizjournals.com - April 22 at 7:47 PMWorcester biopharmaceutical firm Mustang Bio to lay off 81% of staffwbjournal.com - April 18 at 1:45 PMBiotech cites federal review of deal with Chinese firm in latest staff cutsbizjournals.com - April 16 at 9:03 AMMustang Bio stock tumbles 27% amid news of mass layoffsmsn.com - April 15 at 5:59 PMMustang Bio announces major workforce reductioninvesting.com - April 14 at 11:56 AMMustang Bio to Cut Global Headcount by 81%marketwatch.com - April 12 at 8:56 PMMustang Bio Exploring MB-106 CAR T-Cell Candidate in Autoimmune Diseasesprecisionmedicineonline.com - March 29 at 3:32 PMMustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseasesglobenewswire.com - March 28 at 9:00 AMMustang Bio, City of Hope CAR-T therapy extends survival in phase 1 glioblastoma trialfiercebiotech.com - March 12 at 1:35 PMMustang Bio Reports Full-Year 2023 Financial Results and Recent Corporate Highlightsglobenewswire.com - March 11 at 4:05 PMCAR T-Cell Therapy Shows Activity in Subgroup of Brain Tumor Patientstechnologynetworks.com - March 8 at 8:10 AMMustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Ra2-targeted CAR T-Cells in High-Grade Gliomatmcnet.com - March 7 at 9:09 AMWhy Rush Street Interactive Shares Are Trading Higher By Around 25%; Here Are 20 Stocks Moving Premarketmarkets.businessinsider.com - March 7 at 9:09 AMMustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Rα2-targeted CAR T-Cells in High-Grade Gliomaglobenewswire.com - March 7 at 7:30 AMMustang Bio Inc (MBIO)uk.investing.com - February 13 at 2:36 PMMustang Bio to Participate in the B. Riley Securities 4th Annual Oncology Conferencefinance.yahoo.com - January 11 at 9:29 AMMustang Bio Inc MBIOmorningstar.com - January 6 at 12:54 AMMustang Bio Stock (NASDAQ:MBIO) Dividends: History, Yield and Datesbenzinga.com - December 27 at 10:10 PMMBIO Mustang Bio, Inc.seekingalpha.com - December 22 at 10:10 AMMustang Bio: Departure Of Directors Or Certain Officers; Appointment Of Certain Officers; Compensatory Arrangements Of Certain Officerscbonds.com - December 14 at 5:42 PMMustang Bio files to sell 2.74M shares of common stock for holdersmsn.com - December 12 at 1:26 PMMustang Bio’s Positive Financial Performance and Promising Clinical Developments Drive Buy Ratingmarkets.businessinsider.com - November 15 at 8:45 PMMustang Bio, Inc.: Mustang Bio Reports Third Quarter 2023 Financial Results and Recent Corporate Highlightsfinanznachrichten.de - November 15 at 3:44 PMMustang Bio Announces MB-106 CD20-Targeted CAR-T Data Selected for Presentation at 65th American Society of Hematology (ASH) Annual Meetingfinance.yahoo.com - November 2 at 10:51 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsApplied TherapeuticsNASDAQ:APLTApplied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It also develops AT-001 (also called caficrestat) that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.CerecorNASDAQ:CERCCerecor, Inc. is a biopharmaceutical company, which engages in the development and commercialization of treatments for rare and orphan diseases. Its lead product candidates include CERC-801, CERC-802, and CERC-803, which are therapies for inherited metabolic disorders known as congenital disorders of glycosylation. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Rockville, MD.Hookipa PharmaNASDAQ:HOOKHOOKIPA Pharma Inc., a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop arenavirus based therapeutics to treat hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.Mustang BioNASDAQ:MBIOMustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-117 and MB-217, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-101 CAR T cell program for glioblastoma; MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.